Gefetinib
Sorafenib
Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Sorafenib cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Sorafenib The First Affiliated Hospital of Soochow University | Phase 4 | BBB |
Ethiodized Oil Sun Yat-sen University | Phase 3 | B |
Theprubicin Sun Yat-sen University | Phase 3 | B |
Inno-206 Sun Yat-sen University | Phase 3 | B |
Gilteritinib The First Affiliated Hospital of Soochow University | Phase 3 | B |
Toripalimab Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 3 | B |
Same molecule, other indications
Gefetinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →